Introduction:

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality worldwide, associated with the subendothelial deposition of ApoB-rich particles such as LDL cholesterol (LDL-c). Multiple clinical studies highlight the importance of reducing LDL-c and ApoB levels to prevent and manage atherosclerosis. This requires addressing modifiable risk factors and utilizing pharmacological therapies such as statins, ezetimibe, PCSK9 monoclonal antibodies, inclisiran, and bempedoic acid.

Objective:

to review the available evidence on pharmacological therapies and their impact on LDL-c reduction, cardiovascular event prevention, with a focus on adherence and long-term implementation.

Method:

review of scientific literature was conducted, focusing on the effects of lipid-lowering therapies and evaluating their potential impact on cardiovascular event prevention and public health relevance.

Results:

the evaluated therapies reduce the risk of cardiovascular events, with long-term adherence being a key factor. Inclisiran, a small interfering RNA therapy, sustainably lowers LDL-c, and simulation studies demonstrate a significant impact in preventing thousands of cardiovascular events over ten years, with improved adherence.

Conclusion:

Pharmacological therapies, such as inclisiran, represent a significant advance in the management of ASCVD. Their large-scale implementation, combined with lifestyle modifications, can substantially mitigate the burden of cardiovascular disease.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )